Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Diane Havlir, MD
San Francisco General Hospital (SFGH) and University of California San Francisco (UCSF)
Principal Investigator - Joseph K Wong, MD
San Francisco VA Medical Center (SFVAMC) and University of California, San Francisco (UCSF)
Principal Investigator - Steven Yukl, MD
SFVMAC and UCSF
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- San Francisco General Hospital
San Francisco, California, United States
- San Francisco Va Medical Center (sfvamc)
San Francisco, California, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Sept 2008
- Primary completion
- 31 Dec 2009
- Completion
- 31 Dec 2010
- Last update posted
- 23 Jul 2012
- Registered enrollment
- 8
- Registry id
- NCT00884793
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.